Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.


Journal

European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201

Informations de publication

Date de publication:
06 2021
Historique:
revised: 28 12 2020
received: 28 12 2020
accepted: 04 03 2021
pubmed: 19 3 2021
medline: 25 9 2021
entrez: 18 3 2021
Statut: ppublish

Résumé

Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small nuclear RNA (snRNA) and endogenous retroviral elements (ERV) leaking from the nucleus during programmed cell death.

Identifiants

pubmed: 33733474
doi: 10.1002/eji.202049158
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0
Receptors, Cell Surface 0
Robo3 protein, mouse 0
Azacitidine M801H13NRU

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1531-1534

Informations de copyright

© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.

Références

Diamond, M. S. et al., J Experiment Med. 2011. 208: 1989-2003.
Heidegger, S. et al., Sci Immunol. 2019. 4:eaau8943.
Hornung, V. et al., Science. 2006. 314: 994-997.
Besch, R. et al., J Clin Investigat. 2009. 119: 2399-2411.
Duewell, P. et al., Cell Death Differentiat. 2014. 21: 1825-1837.
Vanpouille-Box, C. et al., Vaccine. 2015. 33: 7415-7422.
Ranoa, D. R. et al., Oncotarget. 2016. 7: 26496-26515.
Chiappinelli Katherine, B. et al., Cell. 2015. 162: 974-986.
Gopalakrishnan, V. et al., Science. 2018. 359:97-100.
Routy, B. et al., Science. 2018. 359:91-97.

Auteurs

Hendrik Poeck (H)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
National Centre for Tumor Diseases WERA, Germany.
Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.
Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.

Alexander Wintges (A)

Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

Sarah Dahl (S)

Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

Florian Bassermann (F)

Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.
Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.

Tobias Haas (T)

Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

Simon Heidegger (S)

Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.
Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH